{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Graft+Versus+Host+Disease+Oral&page=2",
    "query": {
      "condition": "Chronic Graft Versus Host Disease Oral",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 511,
    "total_pages": 52,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Graft+Versus+Host+Disease+Oral&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Graft+Versus+Host+Disease+Oral&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T23:30:20.729Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00224055",
      "title": "Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anemia, Iron-Deficiency",
        "Kidney Failure, Chronic"
      ],
      "interventions": [
        {
          "name": "Sodium Ferric Gluconate Complex in Sucrose Injection",
          "type": "DRUG"
        },
        {
          "name": "Ferrous sulfate tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Watson Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2003-04",
      "completion_date": "2004-09",
      "has_results": true,
      "last_update_posted_date": "2012-03-29",
      "last_synced_at": "2026-10-10T23:30:20.729Z",
      "location_count": 23,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Palo Alto, California + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hines",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00224055"
    },
    {
      "nct_id": "NCT00098891",
      "title": "MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Grade III Lymphomatoid Granulomatosis",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Intraocular Lymphoma",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Primary Central Nervous System Non-Hodgkin Lymphoma",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult T-cell Leukemia/Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Small Lymphocytic Lymphoma",
        "Small Intestine Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Stage IV Adult Burkitt Lymphoma",
        "Stage IV Adult Diffuse Large Cell Lymphoma",
        "Stage IV Adult Diffuse Mixed Cell Lymphoma",
        "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage IV Adult Hodgkin Lymphoma",
        "Stage IV Adult Immunoblastic Large Cell Lymphoma",
        "Stage IV Adult Lymphoblastic Lymphoma",
        "Stage IV Adult T-cell Leukemia/Lymphoma",
        "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Stage IV Grade 1 Follicular Lymphoma",
        "Stage IV Grade 2 Follicular Lymphoma",
        "Stage IV Grade 3 Follicular Lymphoma",
        "Stage IV Mantle Cell Lymphoma",
        "Stage IV Marginal Zone Lymphoma",
        "Stage IV Mycosis Fungoides/Sezary Syndrome",
        "Stage IV Small Lymphocytic Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "entinostat",
          "type": "DRUG"
        },
        {
          "name": "isotretinoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2004-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-24",
      "last_synced_at": "2026-10-10T23:30:20.729Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00098891"
    },
    {
      "nct_id": "NCT07053969",
      "title": "The Effect Of Enamel Matrix Derivatives On Gingival Tissue Thickness",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dental Implantation",
        "Missing Teeth",
        "Periodontitis, Adult",
        "Mucositis"
      ],
      "interventions": [
        {
          "name": "Enamel Matrix Derivative",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "18 Years to 18 Years"
      },
      "enrollment_count": 32,
      "start_date": "2025-08-31",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-10-10T23:30:20.729Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07053969"
    },
    {
      "nct_id": "NCT00491894",
      "title": "Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cerebral Palsy",
        "Neurological Conditions",
        "Mental Retardation",
        "Sialorrhea"
      ],
      "interventions": [
        {
          "name": "Oral Glycopyrrolate Liquid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Years to 18 Years"
      },
      "enrollment_count": 137,
      "start_date": "2007-03",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2012-07-09",
      "last_synced_at": "2026-10-10T23:30:20.729Z",
      "location_count": 7,
      "location_summary": "Lakewood, Colorado • Atlanta, Georgia • Bayside, New York + 4 more",
      "locations": [
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Bayside",
          "state": "New York"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Mantua",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00491894"
    },
    {
      "nct_id": "NCT06644183",
      "title": "Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Relapsed Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Relapsed Cancer",
        "Refractory Leukemia"
      ],
      "interventions": [
        {
          "name": "Roginolisib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jennifer R. Brown, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2025-03-19",
      "completion_date": "2032-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-11",
      "last_synced_at": "2026-10-10T23:30:20.729Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06644183"
    },
    {
      "nct_id": "NCT01167166",
      "title": "Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelocytic Leukemia",
        "Acute Lymphocytic Leukemia",
        "Myeloproliferative Disease",
        "Chronic Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "rigosertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Traws Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2010-07",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2017-06-26",
      "last_synced_at": "2026-10-10T23:30:20.729Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01167166"
    },
    {
      "nct_id": "NCT07812246",
      "title": "Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Lymph Node Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Sonrotoclax",
          "type": "DRUG"
        },
        {
          "name": "Zanubrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2027-08-04",
      "completion_date": "2028-08-13",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-10T23:30:20.729Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Irvine, California • Newnan, Georgia",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07812246"
    },
    {
      "nct_id": "NCT04482595",
      "title": "BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "Long COVID",
        "Pulmonary Fibrosis",
        "Post-acute Respiratory Complications of COVID-19"
      ],
      "interventions": [
        {
          "name": "BIO 300 Oral Suspension",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Humanetics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2020-11-11",
      "completion_date": "2025-04-30",
      "has_results": false,
      "last_update_posted_date": "2024-10-01",
      "last_synced_at": "2026-10-10T23:30:20.729Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04482595"
    },
    {
      "nct_id": "NCT01710046",
      "title": "Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "(CP-6890,550) Tofacitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "(CP-690,550) Tofacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2013-03",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2015-04-13",
      "last_synced_at": "2026-10-10T23:30:20.729Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Tampa, Florida • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01710046"
    },
    {
      "nct_id": "NCT03578367",
      "title": "Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CML",
        "Chronic Myelogenous Leukemia",
        "Leukemia, Myeloid Chronic",
        "Hematologic Diseases"
      ],
      "interventions": [
        {
          "name": "Asciminib add-on",
          "type": "DRUG"
        },
        {
          "name": "Imatinib",
          "type": "DRUG"
        },
        {
          "name": "Nilotinib",
          "type": "DRUG"
        },
        {
          "name": "Asciminib 80mg QD (asciminib single agent (ASAC))",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 104,
      "start_date": "2018-11-22",
      "completion_date": "2025-02-26",
      "has_results": true,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-10-10T23:30:20.729Z",
      "location_count": 2,
      "location_summary": "Augusta, Georgia • Baltimore, Maryland",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03578367"
    }
  ]
}